Hormonal
GLP-1 and GIP receptor agonists improve hepatic outcomes in metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH), including resolution of MASH and improvement in fibrosis.
GLP-1 therapies can significantly improve liver health in patients with MASH, including resolving the disease and improving fibrosis in many cases. This benefit is partly due to weight loss but also involves direct effects on liver tissue. Early treatment is crucial, as benefits are not seen in advanced cirrhosis. Patients with fatty liver should discuss these options with their doctor.
Various liraglutide trials have demonstrated reduction in liver fat content by 19–32%... alongside a resolution in steatohepatitis in 39% (compared to 9% in placebo)... The recent interim analysis for the ESSENCE trial in semaglutide 2.4 mg... revealed resolution of MASH without progression of fibrosis in 63% (34% in placebo) at 72 weeks.
Why this rating
Based on RCTs with biopsy-proven endpoints, but some results did not meet statistical significance for fibrosis improvement.
Source
A Narrative Review of the Metabolic Benefits of GLP-1 and GIP Receptor Agonists in Obesity
Andrew-Hyun Lee et al. · Healthcare · 2026
DOI 10.3390/healthcare14060734
More from this paper
- GLP-1 and dual GLP-1/GIP receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant, clinically meaningful weight loss (10-21%) and reduce the incidence of type 2 diabetes in adults with overweight or obesity, with effects rivaling metabolic surgery.Strong
- GLP-1 and GIP receptor agonists reduce major adverse cardiovascular events (MACE) in patients with type 2 diabetes and established cardiovascular disease, independent of weight loss magnitude.Strong
- GLP-1 and GIP receptor agonists improve obstructive sleep apnea (OSA) severity, with tirzepatide being the first medical therapy approved for OSA, showing significant reductions in apnea-hypopnea index (AHI).Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →